Novel tetrahydroacridine derivatives inhibit human lung adenocarcinoma cell growth by inducing G1 phase cell cycle arrest and apoptosis

Biomedicine and Pharmacotherapy

Volumn 68, Issue 8, 2014, Pages 959-967

  Olszewska, Paulina ^a   Mikiciuk Olasik, Elzbieta ^a   Błaszczak Światkiewicz, Katarzyna ^a   Szymański, Jacek ^a   Szymański, Paweł ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acridine derivatives; Anticancer compounds; DNA intercalation; Lung cancer; Tetrahydroacridine derivatives

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; GROWTH INHIBITOR;

ADENOCARCINOMA; APOPTOSIS; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; LUNG NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ACRIDINES; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE CELL CYCLE CHECKPOINTS; GROWTH INHIBITORS; HUMANS; LUNG NEOPLASMS;

EID: 84916602272     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.10.018     Document Type: Article

References (38)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics 2010. CA Cancer J Clin 2010, 60:277-300.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C.D., Parkin D. GLOBOCAN. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2008, International Agency for Research on Cancer 2010, Lyon, France, Available from:,. Last accessed 04 November 2013. http://globocan.iarc.fr/.
3. Collins L.G., Haines C., Perkel R., Enck R. Lung cancer: diagnosis and management. Am Fam Phys 2007, 75:56-63.
4. Dempke W.C.M., Suto T., Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010, 67:257-274.
5. Strasser A., Harris A.W., Jacks T., Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994, 21:329-339.
6. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
7. Cholewiński G., Dzierzbicka K., Kołodziejczyk A.M. Natural and synthetic acridines/acridones as antitumor agents: their biological activities and methods of synthesis. Pharmacol Rep 2011, 63:305-336.
8. Kumar R., Sharma A., Sharma S., Silakari O., Singh M., Kaur M. Synthesis, characterization and antitumor activity of 2-methyl-9-substitued acridines. Arab J Chem 2013, 10.1016/j.arabjc.2012.12.035.
9. da Rocha Pita M.G., Souza E.S., Barros F.W.A., et al. Synthesis and in vitro anticancer activity of novel thiazacridine derivatives. Med Chem Res 2012, 22:2421-2429.
10. Belmont P., Bosson J., Godet T., Tiano M. Acridine and acridone derivatives, anticancer properties and synthetic methods: where are we now?. Anticancer Agents Med Chem 2007, 7:139-169.
11. Ghosh R., Bhowmik S., Guha D. 9-Phenyl acridine exhibits antitumour activity by inducing apoptosis in A375 cells. Moll Cell Biochem 2012, 361:55-66.
12. Sondhi S.M., Singh J., Rani R., Gupta P.P., Agrawal S.K., Saxena A.K. Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives. Eur J Med Chem 2010, 45:555-563.
13. Barros W.A., Bezerra D.P., Ferreira P.M.P., Cavalcanti B.C., Silva T.G., et al. Inhibition of DNA topoisomerase I activity and induction of apoptosis by thiazacridine derivatives. Toxicol Appl Pharm 2013, 268:37-46.
14. Demeunynck M. Antitumor acridines. Expert Opin Ther Pathol 2004, 14:55-70.
15. Nitiss J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta 1998, 1400:63-81.
16. Denny W.A. Acridine derivatives as chemotherapeutic agents. Curr Med Chem 2002, 9:1655-1665.
17. Szymański P., Karpiński A., Mikiciuk-Olasik E. Synthesis, biological activity and HPLC validation of 1,2,3,4-tetrahydroacridine. Eur J Med Chem 2011, 46:3250-3257.
18. Szymański P., Markowicz M., Mikiciuk-Olasik E. Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors. Bioorg Chem 2011, 39:138-142.
19. Szymański P., Markowicz M., Bajda M., Malawska B., Mikiciuk-Olasik E. Synthesis, biological activity and molecular modeling of 4-fluoro-N-[ω-(1,2,3,4-tetrahydroacridin-9-ylamino)-alkyl]-benzamide derivatives as cholinesterase inhibitors. Arzneimittelforschung 2012, 62:655-660.
20. Esposito L., Conti D., Ailavajhala R., Khalil N., Giordano A. Lung cancer: are we up to the challange?. Curr Genomics 2010, 11:513-518.
21. Rosell R., Vergnenegre A., Liu B., Cobo M., Massuti B., Wei J., et al. Biomarkers in lung oncology. Pulmy Pharmacol Ther 2010, 23:508-514.
22. Fernandez M.J., Wilson B., Palacios M., Rodrigo M.M., Grant K.B., Lorente A. Copper-activated DNA photocleavage by a pyridine-linked bis-acridine intercalator. Bioconjug. Chem 2007, 18:121-129.
23. Swenson D.H., Li L.H., Hurley L.H., Rokem J.S., Petzold G.L., Dayton B.D., et al. Mechanism of Interaction of CC-1065 (NSC 298223) with DNA. Cancer Res 1982, 42:2821-2828.
24. Oppegard L.M., Ougolkov A.V., Luchini D.N., Schoon R.A., Goodell J.R., Kaur H., et al. Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalitic inhibitors of human topoisomerase II. Eur J Pharmacol 2009, 14:223-229.
25. Denny W.A., Baguley B.C. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem 2003, 3:339-353.
26. Barros F., Silva T.G., da Rocha Pitta M.G., Bezerra D.P., Costa-Lotufo L.V., de Moraes M.O., et al. Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives. Bioorg Med Chem 2012, 20:3533-3539.
27. Sebestik J., Hlavacek J., Stibor I. A role of the 9-aminoacridines and their conjugates in a life science. Curr Protein Pept Sci 2007, 8:471-483.
28. Olszewska P., Szymański J., Mikiciuk-Olasik E., Szymański P. New cyclopentaquinoline derivatives with fluorobenzoic acid induce G1 arrest and apoptosis in human lung adenocarcinoma cells. Eur J Pharmacol 2014, 729C:30-36.
29. Raza A., Jacobson B.A., Benoit A., Patel M.R., Jay-Dixon J., Hiasa H., et al. Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis. Invest New Drug 2012, 30:1443-1448.
30. Los M., Burek C.J., Stroh C., Benedyk K., Hug H., Mackiewicz A. Anticancer drugs of tomorrow: apoptotic pathways as target for drug design. Drug Discov Today 2003, 8:67-77.
31. Schultz D.R., Harrington W.J. Apoptosis: programmed cell death at molecular level. Semin Arthritis Rheum 2003, 32:345-369.
32. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
33. Ghavami S., Hashemi M., Ane S.R., Yeganeh B., Xiao W., Eshraghi M., et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009, 46:497-510.
34. Fan T.J., Han L.H., Cong R.S., Liang J. Caspase Family Proteases. Acta Biochem Biophys 2005, 37:719-727.
35. Porter A.G., Jänicke R. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999, 6:99-104.
36. Goodell J.R., Ougolkov A.V., Hiasa H., Kaur H., Remmel R., Billadeau D.D., et al. Acridine-based agents with topoisomerase II activity inhibit cancer cell proliferation and induced apoptosis. J Med Chem 2008, 51:179-182.
37. Qiu J., Zhao B., Shen Y., Chen W., Mac Y., Shen Y. A novel p-terphenyl derivative inducing cell-cycle arrest and apoptosis in MDA-MB-435 cells through topoisomerase inhibition. Eur J Med Chem 2013, 68:192-202.
38. Mantena S.K., Sharma S.D., Katiyar S.K. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-depedent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 2006, 5:296-308.